Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Parkinson's Disease Treatments Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Dopamine Agonists
  • 1.3.3 Levodopa
  • 1.3.4 Glutamate Antagonist
  • 1.3.5 Apomorphine
  • 1.3.6 COMT Inhibitors Anticholinergics
  • 1.3.7 MAO-B Inhibitors
  • 1.3.8 Other Drugs
• 1.4 Market Segment by Application
  • 1.4.1 Global Parkinson's Disease Treatments Market Share by Application (2019-2025)
  • 1.4.2 Hospitals
  • 1.4.3 Healthcare Institutes
  • 1.4.4 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Parkinson's Disease Treatments Market Size
  • 2.1.1 Global Parkinson's Disease Treatments Revenue 2014-2025
  • 2.1.2 Global Parkinson's Disease Treatments Sales 2014-2025
• 2.2 Parkinson's Disease Treatments Growth Rate by Regions
  • 2.2.1 Global Parkinson's Disease Treatments Sales by Regions 2014-2019
  • 2.2.2 Global Parkinson's Disease Treatments Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Parkinson's Disease Treatments Sales by Manufacturers
  • 3.1.1 Parkinson's Disease Treatments Sales by Manufacturers 2014-2019
  • 3.1.2 Parkinson's Disease Treatments Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Parkinson's Disease Treatments Revenue by Manufacturers (2014-2019)
  • 3.2.2 Parkinson's Disease Treatments Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Parkinson's Disease Treatments Market Concentration Ratio (CR5 and HHI)
• 3.3 Parkinson's Disease Treatments Price by Manufacturers
• 3.4 Key Manufacturers Parkinson's Disease Treatments Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Parkinson's Disease Treatments Market
• 3.6 Key Manufacturers Parkinson's Disease Treatments Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Dopamine Agonists Sales and Revenue (2014-2019)
  • 4.1.2 Levodopa Sales and Revenue (2014-2019)
  • 4.1.3 Glutamate Antagonist Sales and Revenue (2014-2019)
  • 4.1.4 Apomorphine Sales and Revenue (2014-2019)
  • 4.1.5 COMT Inhibitors Anticholinergics Sales and Revenue (2014-2019)
  • 4.1.6 MAO-B Inhibitors Sales and Revenue (2014-2019)
  • 4.1.7 Other Drugs Sales and Revenue (2014-2019)
• 4.2 Global Parkinson's Disease Treatments Sales Market Share by Type
• 4.3 Global Parkinson's Disease Treatments Revenue Market Share by Type
• 4.4 Parkinson's Disease Treatments Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Parkinson's Disease Treatments Sales by Application

6 United States

• 6.1 United States Parkinson's Disease Treatments Breakdown Data by Company
• 6.2 United States Parkinson's Disease Treatments Breakdown Data by Type
• 6.3 United States Parkinson's Disease Treatments Breakdown Data by Application

7 European Union

• 7.1 European Union Parkinson's Disease Treatments Breakdown Data by Company
• 7.2 European Union Parkinson's Disease Treatments Breakdown Data by Type
• 7.3 European Union Parkinson's Disease Treatments Breakdown Data by Application

8 China

• 8.1 China Parkinson's Disease Treatments Breakdown Data by Company
• 8.2 China Parkinson's Disease Treatments Breakdown Data by Type
• 8.3 China Parkinson's Disease Treatments Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Parkinson's Disease Treatments Breakdown Data by Company
• 9.2 Rest of World Parkinson's Disease Treatments Breakdown Data by Type
• 9.3 Rest of World Parkinson's Disease Treatments Breakdown Data by Application
• 9.4 Rest of World Parkinson's Disease Treatments Breakdown Data by Countries
  • 9.4.1 Rest of World Parkinson's Disease Treatments Sales by Countries
  • 9.4.2 Rest of World Parkinson's Disease Treatments Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 GSK
  • 10.1.1 GSK Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Parkinson's Disease Treatments
  • 10.1.4 Parkinson's Disease Treatments Product Introduction
  • 10.1.5 GSK Recent Development
• 10.2 Merck
  • 10.2.1 Merck Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Parkinson's Disease Treatments
  • 10.2.4 Parkinson's Disease Treatments Product Introduction
  • 10.2.5 Merck Recent Development
• 10.3 Novartis
  • 10.3.1 Novartis Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Parkinson's Disease Treatments
  • 10.3.4 Parkinson's Disease Treatments Product Introduction
  • 10.3.5 Novartis Recent Development
• 10.4 Teva
  • 10.4.1 Teva Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Parkinson's Disease Treatments
  • 10.4.4 Parkinson's Disease Treatments Product Introduction
  • 10.4.5 Teva Recent Development
• 10.5 Boehringer Ingelheim
  • 10.5.1 Boehringer Ingelheim Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Parkinson's Disease Treatments
  • 10.5.4 Parkinson's Disease Treatments Product Introduction
  • 10.5.5 Boehringer Ingelheim Recent Development
• 10.6 Impax
  • 10.6.1 Impax Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Parkinson's Disease Treatments
  • 10.6.4 Parkinson's Disease Treatments Product Introduction
  • 10.6.5 Impax Recent Development
• 10.7 Abbvie
  • 10.7.1 Abbvie Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Parkinson's Disease Treatments
  • 10.7.4 Parkinson's Disease Treatments Product Introduction
  • 10.7.5 Abbvie Recent Development
• 10.8 Valeant Pharmaceuticals
  • 10.8.1 Valeant Pharmaceuticals Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Parkinson's Disease Treatments
  • 10.8.4 Parkinson's Disease Treatments Product Introduction
  • 10.8.5 Valeant Pharmaceuticals Recent Development
• 10.9 Lundbeck
  • 10.9.1 Lundbeck Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Parkinson's Disease Treatments
  • 10.9.4 Parkinson's Disease Treatments Product Introduction
  • 10.9.5 Lundbeck Recent Development
• 10.10 Sun Pharma
  • 10.10.1 Sun Pharma Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Parkinson's Disease Treatments
  • 10.10.4 Parkinson's Disease Treatments Product Introduction
  • 10.10.5 Sun Pharma Recent Development
• 10.11 Wockhardt
• 10.12 Acadia
• 10.13 UCB

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Parkinson's Disease Treatments Sales Channels
  • 11.2.2 Parkinson's Disease Treatments Distributors
• 11.3 Parkinson's Disease Treatments Customers

12 Market Forecast

• 12.1 Global Parkinson's Disease Treatments Sales and Revenue Forecast 2019-2025
• 12.2 Global Parkinson's Disease Treatments Sales Forecast by Type
• 12.3 Global Parkinson's Disease Treatments Sales Forecast by Application
• 12.4 Parkinson's Disease Treatments Forecast by Regions
  • 12.4.1 Global Parkinson's Disease Treatments Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Parkinson's Disease Treatments Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Parkinson’s disease is a central nervous system syndrome which affects the motor neuron, mainly characterized by rigidity, tremor, depression, dementia, and so on. Treatment for this disease is mostly symptomatic and almost no curative treatment alternatives are available.
In 2019, the market size of Parkinson's Disease Treatments is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Parkinson's Disease Treatments.

This report studies the global market size of Parkinson's Disease Treatments, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Parkinson's Disease Treatments sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
GSK
Merck
Novartis
Teva
Boehringer Ingelheim
Impax
Abbvie
Valeant Pharmaceuticals
Lundbeck
Sun Pharma
Wockhardt
Acadia
UCB

Market Segment by Product Type
Dopamine Agonists
Levodopa
Glutamate Antagonist
Apomorphine
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Other Drugs

Market Segment by Application
Hospitals
Healthcare Institutes
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Parkinson's Disease Treatments status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Parkinson's Disease Treatments manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Parkinson's Disease Treatments are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025